Evogene (EVGN) said Monday it has struck a deal for ICL to acquire the majority of activity of its subsidiary, Lavie Bio, which focuses on improving agriculture productivity.
The company said ICL will also acquire its MicroBoost AI for AG platform as part of the agreement.
Evogene said key assets to be transferred to ICL include Lavie Bio's core team, the BDD technology platform, microbial bank and data assets. It expects to close the deal in Q2.
"This transaction reflects Evogene's ongoing strategy to unlock the value of its assets for the benefit of its shareholders," said Chief Executive Ofer Haviv.
The shares shares were up about 20% in recent trading.
Price: 1.17, Change: +0.20, Percent Change: +20.62
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。